HOOKIPA Pharma IncNASDAQ:HOOKNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7650
- TODAY'S CHANGE (%)0.0150 (2.0000%)
- Bid / Lots0.7600/ 2
- Ask / Lots0.7650/ 2
- Open / Previous Close0.7573 / 0.7500
- Day Range
- 52 Week Range
- Volume35,710
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HOOK |
|---|---|---|
| 09:32 ET | 8643 | 0.76 |
| 09:34 ET | 500 | 0.75 |
| 09:39 ET | 170 | 0.76 |
| 09:41 ET | 302 | 0.765 |
| 09:48 ET | 11731 | 0.765 |
| 09:50 ET | 995 | 0.765 |
May 23, 2024
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting, from 5:01PM ET on Thursday May 23, 2024 by Dow Jones
5:01PM ET on Thursday May 23, 2024 by Dow Jones
May 21, 2024
DJ HOOKIPA Pharma Price Target Maintained With a $5.00/Share by RBC Capital, from 1:21PM ET on Tuesday May 21, 2024 by Dow Jones
1:21PM ET on Tuesday May 21, 2024 by Dow Jones
May 9, 2024
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights, from 7:01AM ET on Thursday May 09, 2024 by Dow Jones
7:01AM ET on Thursday May 09, 2024 by Dow Jones*DJ HOOKIPA Pharma 1Q EPS 11c >HOOK, from 7:01AM ET on Thursday May 09, 2024 by Dow Jones
7:01AM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
HOOKIPA Pharma Inc | 74.2M | 0.0x | --- |
Company Information
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.
Contact Information
- Headquarters
- 350 Fifth Avenue, 72Nd Floor, Suite 7240NEW YORK, NY, United States 10118
- Phone
- ---
- Fax
- 302-655-5049
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $74.2M |
|---|---|
Revenue (TTM) | $53.6M |
Shares Outstanding | 99.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.74 |
EPS | $-0.59 |
Book Value | $0.91 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 1.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -119.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
